Under the present medical system, the influence of human genome is very limited, because of some basic challenges: the providers cannot receive the related resources in time, which can be used to reveal the increasingly complicated genome data; lots of hospitals and labs lack of the professional knowledge of information and genome science, unable to structure and manage the high-throughput sequencing; the genome researchers are difficult to get effective data, and connect DNA with human health. Against this situation, the gene sequencing company Phosphorus aims to establish a genome data network, for the purpose to enable providers, researchers and patients get further known about the power of human genome,and make full use of it.

Recently, the gene sequencing company Phosphorus announced the finish of 10 million A round financing, which leading by FirstMark Capital, and joined with the company’s own founder and several angel investors. The company intends to using this capital to expand the computer scientists, engineers and geneticists teams, therefore promoting the new clinical trails and software products development.

Phosphorus just spin off the genome company Recombine this year, founded by Alexander Bisignano, the co-founder and CEO of Recombine, accompanied with the computer scientists and engineer team in the original department. Before this, Recombine has a medical test, sequencing the gene of the couples preparing pregnant, therefore can get to know the potential possibilities of genetic diseases or recessive mutations that may influence the children in the future. Last year, Recombine acquired by CooperSurgical under the price of 85 million dollars, and the this medical test has been acquired simultaneously, however, Recombine saved the software platform of the test and the data map as well. Hence, Phosphorus can use the related data map resources continually.

The fertilityMap research that Phosphorus processing is able to examine any possible indications of infertility for couples, clients can take corresponded prevention measures to prevent from the potential infertility. Besides, relevant researchers can use the products for their own research. The data and necessary resources are also available for fertility clinics and direct clients.

Bisignano states that, “We found Phosphorus, make it at the hinge position of the new generation of computer bio-science. Our goal is to establish the platform, which can make the laboratories all over the world are able to provide advanced gen-test more convenient, help to get more accurate patient diagnosis result.

In the future days, Phosphorus will continue working with CooperSurgical, to support the commercial test products delivery.